RESEARCH TRIANGLE PARK – LaunchBio’s inaugural Invest in Cures forum packed the house at the North Carolina Biotechnology Center last week.
The opening panel drew the attention of attendees.
Execs search for best ways to capitalize on nonprofits’ growing investments in cures search
Eric Linsley (left), Managing General Partner of BioInnovation Capital; Ben Yerxa (second from left) of Retinal Degeneration Fund; Barbara Tate (second from right) of Dementia Discovery Fund; and John Behr (right) of T1D Fund discuss the impact investing trend in life sciences and share their investment philosophies.
In the second panel of the night, “How the Deal was Done”, Bill Wofford (left), who heads the biotechnology and life sciences practice at Hutchison PLLC, Debra Miller (second from left), CEO of CureDuchenne Ventures; Rich West (second from right), CEO of Baebies; and Chris Penland (right),VP of Biopharma Programs at Cystic Fibrosis Foundation, discuss deals that were recently inked between disease foundations and NC-based life science companies.
Debra Miller and Rich West talked about the investment CureDuchenne recently made into Baebies.
Christy Shaffer, General Partner at Hatteras Venture Partners (left); Gerard Honig, Manager of Translational Research at IBD Ventures (second from left); Bob Cruthfield, Managing Director of BrightEdge Ventures; Wellington Pak, President of FHI Ventures (second from right); and Mark Allegretta, Associate VP, Commercial Research at National Multiple Sclerosis Society (right), discuss what disease foundations look for in early stage companies.
Faces in the crowd
The event closed with a great deal of networking.
CureDuchenne and Baebies: How a nonprofit and biotech startup are fighting ‘to save babies’
